United States · Platforms & data · The Motley Fool

Replimune (REPL) Q2 2027 Earnings Call Transcript

Published by The Motley Fool · United States 1 h ago

TUDRIQEV launched with $450,000 price tag and early traction across oncology institutions.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

American Airlines Group (NASDAQ:AAL) Stock Price Target Cut by Freedom Broker

Universal Display expects full-year revenue toward low end of $630M-$670M range as OLEDX and NovaJet launch

ServiceNow’s stock slides as earnings miss overshadows a raised AI outlook

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Meta, Snap Reportedly Face New US Trial Over Youth Social Media Addiction Claims — Zuckerberg, Spiegel Expected To Testify

Market News